|
Supplemental
ascorbate in the supportive treatment of cancer: Prolongation of survival times
in terminal human cancer
Cameron E, Pauling L
Ascorbic
acid metabolism is associated with a number of mechanisms known to be involved
in host resistance to malignant disease.
Cancer patients are significantly depleted of ascorbic acid, and in our opinion
this demonstrable biochemical characteristic indicates a substantially increased
requirement and utilization of this substance to potentiate these various host
resistance factors.
The results of a clinical trial are presented in which 100 terminal cancer
patients were given supplemental ascorbate as part of their routine management.
Their progress is compared to that of 1000 similar patients treated identically,
but who received no supplemental ascorbate. The mean survival time is more than
4.2 times as great for the ascorbate subjects (more than 210 days) as for the
controls (50 days).
Analysis of the survival-time curves indicates that deaths occur for about 90%
of the ascorbate-treated patients at one-third the rate for the controls and
that the other 10% have a much greater survival time, averaging more than 20
times that for the controls.
The results clearly indicate that this simple and safe form of medication is of
definite value in the treatment of patients with acvanced cancer.
PMID:
1068480 [PubMed - indexed for MEDLINE]
|
